Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 109

1.

Pharmacogenetics: Point-of-care genetic testing--a new frontier explored.

Barrett PM, Topol EJ.

Nat Rev Cardiol. 2012 May 1;9(6):315-6. doi: 10.1038/nrcardio.2012.63. No abstract available.

PMID:
22547169
2.

Optimizing platelet inhibition in clopidogrel poor metabolizers: therapeutic options and practical considerations.

Angiolillo DJ, Ueno M.

JACC Cardiovasc Interv. 2011 Apr;4(4):411-4. doi: 10.1016/j.jcin.2011.03.001. No abstract available.

3.

The worry about clopidogrel "nonresponsiveness": identification and treatment in the post-percutaneous coronary intervention patient.

Gurbel PA, Tantry US, Shuldiner AR.

JACC Cardiovasc Interv. 2009 Nov;2(11):1102-4. doi: 10.1016/j.jcin.2009.09.005. No abstract available.

4.

Phenotyping vs. genotyping for prediction of clopidogrel efficacy and safety: the PEGASUS-PCI study.

Siller-Matula JM, Delle-Karth G, Lang IM, Neunteufl T, Kozinski M, Kubica J, Maurer G, Linkowska K, Grzybowski T, Huber K, Jilma B.

J Thromb Haemost. 2012 Apr;10(4):529-42. doi: 10.1111/j.1538-7836.2012.04639.x.

5.

Pharmacogenetics testing: implications for cardiovascular therapeutics with clopidogrel and warfarin.

George J, Doney A, Palmer CN, Lang CC.

Cardiovasc Ther. 2010 Jun;28(3):135-8. doi: 10.1111/j.1755-5922.2010.00176.x. No abstract available.

PMID:
20557312
6.

Routine assessment of on-clopidogrel platelet reactivity and gene polymorphisms in predicting clinical outcome following drug-eluting stent implantation in patients with stable coronary artery disease.

Viviani Anselmi C, Briguori C, Roncarati R, Papa L, Visconti G, Focaccio A, De Micco F, Latronico MV, Pagnotta P, Condorelli G.

JACC Cardiovasc Interv. 2013 Nov;6(11):1166-75. doi: 10.1016/j.jcin.2013.06.010.

7.

Antiplatelet therapy: Does CYP2C19 genotype affect clinical outcome?

ten Berg JM, Deneer VH.

Nat Rev Cardiol. 2012 Mar 13;9(4):192-4. doi: 10.1038/nrcardio.2012.29. No abstract available.

PMID:
22411289
8.

Point-of-care genetic testing for personalisation of antiplatelet treatment (RAPID GENE): a prospective, randomised, proof-of-concept trial.

Roberts JD, Wells GA, Le May MR, Labinaz M, Glover C, Froeschl M, Dick A, Marquis JF, O'Brien E, Goncalves S, Druce I, Stewart A, Gollob MH, So DY.

Lancet. 2012 May 5;379(9827):1705-11. doi: 10.1016/S0140-6736(12)60161-5. Epub 2012 Mar 29.

PMID:
22464343
9.

Acceptance of high platelet reactivity as a risk factor: now, what do we do about it?

Gurbel PA, Tantry US.

JACC Cardiovasc Interv. 2010 Oct;3(10):1008-10. doi: 10.1016/j.jcin.2010.08.011. No abstract available.

10.

The common gene variants of CYP2C19 affect pharmacokinetics and pharmacodynamics in an active metabolite of clopidogrel in healthy subjects.

Umemura K, Furuta T, Kondo K.

J Thromb Haemost. 2008 Aug;6(8):1439-41. doi: 10.1111/j.1538-7836.2008.03050.x. Epub 2008 Jun 4. No abstract available.

11.

Clinical Pharmacogenetics Implementation Consortium guidelines for cytochrome P450-2C19 (CYP2C19) genotype and clopidogrel therapy.

Scott SA, Sangkuhl K, Gardner EE, Stein CM, Hulot JS, Johnson JA, Roden DM, Klein TE, Shuldiner AR; Clinical Pharmacogenetics Implementation Consortium.

Clin Pharmacol Ther. 2011 Aug;90(2):328-32. doi: 10.1038/clpt.2011.132. Epub 2011 Jun 29. Review. No abstract available.

12.

Current evidence for genetic testing in clopidogrel-treated patients undergoing coronary stenting.

Sibbing D, Bernlochner I, Kastrati A, Paré G, Eikelboom JW.

Circ Cardiovasc Interv. 2011 Oct 1;4(5):505-13; discussion 513. doi: 10.1161/CIRCINTERVENTIONS.111.962183. Review. No abstract available.

13.

Pharmacogenomics of clopidogrel: evidence and perspectives.

Yin T, Miyata T.

Thromb Res. 2011 Oct;128(4):307-16. doi: 10.1016/j.thromres.2011.04.010. Epub 2011 May 18. Review.

PMID:
21592545
14.

Clinical Pharmacogenetics Implementation Consortium guidelines for CYP2C19 genotype and clopidogrel therapy: 2013 update.

Scott SA, Sangkuhl K, Stein CM, Hulot JS, Mega JL, Roden DM, Klein TE, Sabatine MS, Johnson JA, Shuldiner AR; Clinical Pharmacogenetics Implementation Consortium.

Clin Pharmacol Ther. 2013 Sep;94(3):317-23. doi: 10.1038/clpt.2013.105. Epub 2013 May 22.

15.

Clopidogrel and the reduced-function CYP2C19 genetic variant: a limited piece of the overall therapeutic puzzle.

Fuster V, Sweeny JM.

JAMA. 2010 Oct 27;304(16):1839-40. doi: 10.1001/jama.2010.1566. No abstract available.

PMID:
20978263
16.

Current status of clopidogrel pharmacogenomics.

Giusti B, Gori AM, Marcucci R, Abbate R.

Pharmacogenomics. 2012 Nov;13(15):1671-4. doi: 10.2217/pgs.12.153. No abstract available.

PMID:
23171330
17.

The pharmacogenomics of clopidogrel.

Levitt MR, Osbun JW, Kim LJ.

World Neurosurg. 2012 Mar-Apr;77(3-4):406-7. doi: 10.1016/j.wneu.2012.02.040. Epub 2012 Feb 11. No abstract available.

PMID:
22366366
18.

Platelet inhibition by adjunctive cilostazol versus high maintenance-dose clopidogrel in patients with acute myocardial infarction according to cytochrome P450 2C19 genotype.

Kim IS, Jeong YH, Park Y, Park KS, Yun SE, Park JR, Hwang SJ, Koh EH, Kwak CH, Hwang JY, Kim S.

JACC Cardiovasc Interv. 2011 Apr;4(4):381-91. doi: 10.1016/j.jcin.2010.12.010.

19.

Pharmacogenetics and cardiovascular disease--implications for personalized medicine.

Johnson JA, Cavallari LH.

Pharmacol Rev. 2013 May 17;65(3):987-1009. doi: 10.1124/pr.112.007252. Print 2013 Jul. Review.

20.

Clopidogrel and the concept of high-risk pharmacokinetics.

Roden DM, Stein CM.

Circulation. 2009 Apr 28;119(16):2127-30. doi: 10.1161/CIRCULATIONAHA.109.865907. No abstract available.

Supplemental Content

Support Center